Arkolith/Insider Trading/LXRX/Form 4

Coiante Scott M

SVP, Chief Financial OfficerLEXICON PHARMACEUTICALS, INC. (LXRX) · full profile →Form 4 · filed Mar 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 28, 2026Option exercise(M)160K——160K
Feb 28, 2026Tax withholding(F)55K$1.47$81K105K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2026Option exercise(M)160K——320K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062822-26-000035) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML